 Home > Active Ingredient News > Antitumor Therapy > Cancers: Efficacy and safety of Pertuzumab and Trastuzumab combined with local radiotherapy in the treatment of patients with HER2-positive breast cancer

Cancers: Efficacy and safety of Pertuzumab and Trastuzumab combined with local radiotherapy in the treatment of patients with HER2-positive breast cancer

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

navicular horses treatment

gingivitis natural treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

HER2 receptor (human epidermal growth factor receptor 2) in the presence of overexpression of 15--30% of the breast cancer in
.

Trastuzumab is the first humanized monoclonal antibody directed against the HER2 receptor, and its efficacy in HER2-positive breast cancer has been proven

HER2 receptor (human epidermal growth factor receptor 2) in the presence of overexpression of 15--30% of the breast cancer in

The study finally included 55 patients with a median age of 53 years (range: 28-81 years)
.

The tumor histology of the vast majority of patients (94.

The study finally included 55 patients with a median age of 53 years (range: 28-81 years)

Clinical features

During Pertuzumab/Trastuzumab dual HER2 blockade treatment, all patients had received chemotherapy, including docetaxel (69.
1%), paclitaxel (9.
1%) and epirubicin (14.
5%)
.

A total of 10 patients (18.

During Pertuzumab/Trastuzumab dual HER2 blockade treatment, all patients had received chemotherapy, including docetaxel (69.

Skin toxicity: Early poisoning included 3 cases (5.

The median follow-up time after radiotherapy was 4.

The 4-year progression-free survival rate (PFS) was 65.
7% (51.
7%-83.
6%)
.

The 4-year progression-free survival rate (PFS) was 65.

PFS

The 4-year local recurrence-free survival rate (LRRFS) was 97.
1% (91.
5%-100%)
.

The median OS, PFS and LRRFS were not reached

The 4-year local recurrence-free survival rate (LRRFS) was 97.

Local recurrence-free survival rate (LRRFS)

Local recurrence-free survival rate (LRRFS) Local recurrence-free survival rate (LRRFS)

In summary, the study shows that the combination of local breast radiotherapy (RT) and Pertuzumab/trastuzumab dual HER2 blockade is well tolerated, suggesting that patients with HER2-positive breast cancer can safely join RT
.
The study showed that the combination of local breast radiotherapy (RT) and Pertuzumab/trastuzumab dual HER2 blockade is well tolerated, suggesting that patients with HER2-positive breast cancer can safely join RT
.
The study showed that the combination of local breast radiotherapy (RT) and Pertuzumab/trastuzumab dual HER2 blockade is well tolerated, suggesting that patients with HER2-positive breast cancer can safely join RT
.

Original source:

Aboudaram, A.
; Loap, P.
;Loirat, D.
; Dhia, SB; Cao, K.
; etal.
Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression.
Cancers 2021, 13, 4790.
https://doi.
org/10.
3390/cancers 13194790

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.